Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleAccepted Articles
Open Access

Treatment response to tumor necrosis factor inhibitors and methotrexate monotherapy in adults with juvenile idiopathic arthritis: Data from NORDMARD

Imane Bardan, Karen Minde Fagerli, Joe Sexton, Tore K. Kvien, Gunnstein Bakland, Pawel Mielnik, Yi Hu, Gunhild Lien, Berit Flatø, Øyvind Molberg, Eirik Klami Kristianslund and Anna-Birgitte Aga
The Journal of Rheumatology November 2022, jrheum.220645; DOI: https://doi.org/10.3899/jrheum.220645
Imane Bardan
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen Minde Fagerli
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joe Sexton
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tore K. Kvien
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gunnstein Bakland
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pawel Mielnik
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi Hu
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gunhild Lien
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Berit Flatø
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Øyvind Molberg
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eirik Klami Kristianslund
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna-Birgitte Aga
Faculty of Medicine, University of Oslo, Oslo, Norway; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway; Section for Rheumatology, Department for Neurology, Rheumatology and Physical Medicine, Helse Førde HF, Førde, Norway; Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway; Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. Funding statement: This work was supported by Faculty of Medicine, University of Oslo, Oslo, Norway. Conflicts of interest: Imane Bardan: None declared, Karen Minde Fagerli: None declared, Joe Sexton: None declared, Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Consultant of Galapagos , Yi Hu: None declared, Tore K. Kvien Speakers bureau: Fees for speaking: Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Fees for consulting: AbbVie, Amgen, Biogen, Celltrion, Eli Lilly, Galapagos, Gliead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Received research funding to Diakonhjemmet Hospital from Abbvie, Amgen, BMS, Galapagos, MSD, Pfizer and UCB, Gunhild Lien: None declared, Berit Flatø: None declared, Øyvind Molberg: None declared, Eirik Kristianslund: None declared, Anna-Birgitte Aga: personal fees from Abbvie, Eli Lilly, Novartis and Pfizer, outside the submitted work Correspondence to: Imane Bardan, Faculty of Medicine, University of Oslo, PO Box 1078 Blindern, 0316 Oslo, Norway. E-mail: imane.bardan@studmed.uio.no
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

Abstract

Objective Compare effectiveness of tumor necrosis factor inhibitors (TNFi) ± comedication and methotrexate monotherapy (MTX mono) between adult juvenile idiopathic arthritis (JIA) and rheumatoid arthritis (RA) patients.

Methods Adult JIA and RA patients were identified from the NOR-DMARD register. Disease activity measurements at baseline, 3, 6 and 12 months were compared between JIA and RA patients starting (1) TNFi and (2) MTX monotherapy, using age- and gender-weighted analyses. We calculated differences between JIA and RA in mean changes in DAS28, CDAI and SDAI, among other disease activity measures. DAS28, CDAI, SDAI and ACR/EULAR remission rates at 3, 6 and 12 months, as well as 6- and 12-month LUNDEX-corrected rates, were calculated.

Results We identified 478 JIA patients (TNFi/MTX mono N=358/120) and 4637 RA patients (N=2292/2345). JIA patients had lower baseline disease activity compared to RA patients across treatment groups. After baseline disease activity adjustment there were no significant differences in disease activity change from baseline to 3, 6 and 12-months follow-up between JIA and RA patients for either treatment group. 12- month remission rates were similar between groups based on DAS28 (TNFi: JIA 55.2%, RA 49.5%. MTX mono: JIA 45.3%, RA 41.2%) and ACR/EULAR remission criteria (TNF: JIA 20.4%, RA 20.0%. MTX mono: JIA 17.0%, RA 12.7%). Median drug survival (years) was similar for JIA and RA in both treatment groups (TNFi: JIA 1.2, RA 1.4; MTX mono: JIA 1.3, RA 1.6)

Conclusion TNFi and MTX mono are effective in adult JIA, with similar effectiveness as in RA.

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 52, Issue 6
1 Jun 2025
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Treatment response to tumor necrosis factor inhibitors and methotrexate monotherapy in adults with juvenile idiopathic arthritis: Data from NORDMARD
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Accepted manuscript
Treatment response to tumor necrosis factor inhibitors and methotrexate monotherapy in adults with juvenile idiopathic arthritis: Data from NORDMARD
Imane Bardan, Karen Minde Fagerli, Joe Sexton, Tore K. Kvien, Gunnstein Bakland, Pawel Mielnik, Yi Hu, Gunhild Lien, Berit Flatø, Øyvind Molberg, Eirik Klami Kristianslund, Anna-Birgitte Aga
The Journal of Rheumatology Nov 2022, jrheum.220645; DOI: 10.3899/jrheum.220645

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Accepted manuscript
Treatment response to tumor necrosis factor inhibitors and methotrexate monotherapy in adults with juvenile idiopathic arthritis: Data from NORDMARD
Imane Bardan, Karen Minde Fagerli, Joe Sexton, Tore K. Kvien, Gunnstein Bakland, Pawel Mielnik, Yi Hu, Gunhild Lien, Berit Flatø, Øyvind Molberg, Eirik Klami Kristianslund, Anna-Birgitte Aga
The Journal of Rheumatology Nov 2022, jrheum.220645; DOI: 10.3899/jrheum.220645
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Modifiable lifestyle factors, genetic susceptibility, and incident ankylosing spondylitis
  • Patterns of Use and Discontinuation for Tumour Necrosis Factor Inhibitors in Pregnant Women: Insights from a Real-World Sample
  • Long-term effectiveness and safety of denosumab for osteoporosis in patients with rheumatic diseases
Show more Accepted Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire